Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 10/20 | 0.56 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.56 |
| ▸ | MTOR | P42345 | 6/20 | 0.46 |
| ▸ | KDR | P35968 | 6/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.46 |
| ▸ | PRKDC | P78527 | 5/20 | 0.46 |
| ▸ | ABL1 | P00519 | 3/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | HCK | P08631 | 3/20 | 0.46 |
| ▸ | SRC | P12931 | 3/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.46 |
| ▸ | RET | P07949 | 5/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL29669807 | 1.00 | PIK3CD (0.56) | PIK3CDPIK3CGMTORKDRPIK3CA | |
| SCHEMBL20552797 | 0.92 | PIK3CD (0.64) | PIK3CDPIK3CGMTORKDRPIK3CA | |
| SCHEMBL30405222 | 0.92 | PIK3CD (0.64) | PIK3CDPIK3CGMTORKDRPIK3CA | |
| Trifluoroacetic Acid SCHEMBL21528272 | 0.89 | PIK3CG (0.54) | PIK3CDPIK3CGMTORKDRPIK3CA | |
| Trifluoroacetic Acid SCHEMBL29669697 | 0.89 | PIK3CG (0.54) | PIK3CDPIK3CGMTORKDRPIK3CA | |
| SCHEMBL20553552 | 0.85 | PIK3CD (0.45) | PIK3CDPIK3CGMTORKDRPIK3CA | |
| Trifluoroacetic Acid SCHEMBL21528139 | 0.84 | RET (0.54) | PIK3CDPIK3CGMTORKDRPIK3CA | |
| Trifluoroacetic Acid SCHEMBL21528199 | 0.84 | RET (0.55) | PIK3CDPIK3CGMTORKDRPIK3CA | |
| Trifluoroacetic Acid SCHEMBL29669791 | 0.84 | RET (0.54) | PIK3CDPIK3CGMTORKDRPIK3CA | |
| Trifluoroacetic Acid SCHEMBL29669754 | 0.84 | RET (0.55) | PIK3CDPIK3CGMTORKDRPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166667-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| EP-4234031-A2 | C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-11685749-B2 | C26-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230093861-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. | 2023-03-30 | — | — | US | disclosed |
| EP-3788049-B1 | C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | REVOLUTION MEDICINES INC (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20230055672-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-02-23 | — | — | US | disclosed |
| US-11364300-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210338824-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-11-04 | — | — | US | disclosed |
| US-10980889-B1 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20210094975-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. | 2021-04-01 | — | — | US | disclosed |
| EP-3619216-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2020-03-11 | — | — | EP | disclosed |
| US-20190336609-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | Revolution Medicines, Inc. | 2019-11-07 | — | — | US | disclosed |
| WO-2018204416-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | Revolution Medicines, Inc. (US) | 2018-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230093861-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | PIK3CD 117/4885PIK3CG 195/4885MTOR 1/4885 |
| US-11685749-B2 | C26-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | PIK3CD 142/4885PIK3CG 191/4885MTOR 1/4885 |
| US-10980889-B1 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | PIK3CD 94/4885PIK3CG 120/4885MTOR 1/4885 |
| US-20210338824-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | PIK3CD 94/4885PIK3CG 120/4885MTOR 1/4885 |
| US-20190336609-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | PIK3CD 94/4885PIK3CG 120/4885MTOR 1/4885 |
| US-20240166667-A1 | C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | PIK3CD 142/4885PIK3CG 191/4885MTOR 1/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | PIK3CD 215/4885PIK3CG 243/4885MTOR 3/4885 |
| US-11364300-B2 | C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | PIK3CD 94/4885PIK3CG 120/4885MTOR 1/4885 |
| US-20230055672-A1 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | MTOR, RICTOR, RPTOR | PIK3CD 94/4885PIK3CG 120/4885MTOR 1/4885 |
| US-20210094975-A1 | RAPAMYCIN ANALOGS AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | PIK3CD 117/4885PIK3CG 195/4885MTOR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.